Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ISRCTN |
Last refreshed on:
|
13 March 2017 |
Main ID: |
ISRCTN54805841 |
Date of registration:
|
18/03/2010 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
Testing the feasibility of nicotine-assisted reduction to stop in pharmacies
|
Scientific title:
|
Testing the feasibility of nicotine-assisted reduction to stop in pharmacies: a 2x2 factorial trial |
Date of first enrolment:
|
02/06/2010 |
Target sample size:
|
320 |
Recruitment status: |
Completed |
URL:
|
http://isrctn.com/ISRCTN54805841 |
Study type:
|
Interventional |
Study design:
|
Multicentre randomised 2x2 factorial design controlled parallel group trial (Prevention)
|
Phase:
|
Not Specified
|
|
Countries of recruitment
|
United Kingdom
| | | | | | | |
Contacts
|
Name:
|
Taina
Taskila |
Address:
|
The University of Birmingham
Edgbaston
B15 2TT
Birmingham
United Kingdom |
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: 1. Male or female, 18 years or older 2. Smokes at least 10 cigarettes or 12.5g of loose tobacco daily as roll your own cigarettes, or blows 15ppm or above on CO recording 3. Do not intend to stop in the next month, but are prepared to reduce their consumption with any of the programmes offered 4. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study and consents to participate and be randomised to either arm and have either a telephone or email for follow-up
Exclusion criteria: 1. Currently using other NRT, bupropion, nortriptyline, mecamylamine, reserpine, or varenicline, or undergoing any treatment for tobacco dependence (e.g. acupuncture), 2. Unstable angina pectoris, myocardial infarction, or cerebrovascular accident during the last 3 weeks, 3. Severe cardiac arrhythmia 4. Currently uncontrolled hyperthyroidism 5. Active phaeocromocytoma 6. Pregnancy, lactation or intended pregnancy 7. Participation in other medicinal trials within the last three months and during study participation, 8. Previously had severe skin reactions to nicotine patches or severe eczema or other skin diseases that make patch use hazardous or undesirable 9. Severe acute or chronic medical or psychiatric condition or previously diagnosed clinically important renal or hepatic disease, that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study
Age minimum:
Age maximum:
Gender:
Both
|
Health Condition(s) or Problem(s) studied
|
Public Health Mental and Behavioural Disorders
|
Intervention(s)
|
This trial has a 2x2 factorial design. The pharmacists will recruit 16 patients per pharmacy; 160 smokers altogether. Participants will be randomised in sealed envelopes to receive: 1. Behavioural support 1.1. 52 weeks 1.2. 4 weeks The pharmacist will give support for 52 weeks by inviting participants to set a treatment goal and provide advice on how to reduce cigarettes. Participants in the 4-week supported programme will be given the same advice with the reduction but with a different schedule. Participants will be provided with a weeks worth of Nicotine Replacement Therapy every week for the duration of their participation in the trial. 2. No support 2.1. 52 weeks 2.2. 4 weeks Participants in the no support arms will not be given advice or support. Instead they will be given a leaflet that describes the reduction programmes, and encourages use of Nicotine Replacement Therapy (NRT) to support the reduction.
The trial will run for 52 weeks regardless of the trial arm, it is only the way they reduce the amount they smoke that will differ. The NRT will be given by the recruiting pharmacist. The participants will also be asked to provide a CO2 reading at their first appointment, at the last appointment and also after every time they have gone smoke free for a month.
|
Primary Outcome(s)
|
1. Hospital Anxiety Depression Scale (HADS) measured at baseline and the end of follow up (52 weeks) 2. Smoking behaviour measured at baseline 3. Service satisfaction questionnaire at end of follow up (52 weeks)
|
Secondary Outcome(s)
|
Cessation activity: at 4 wks, 8 wks, 12, 16, 20, 24 etc. every month until the end of the trial (52 weeks) (11 measures)
|
Source(s) of Monetary Support
|
Medical Research Council (MRC) (UK) - National Prevention Research Initiative (NPRI) (ref: G0802135)
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|